Search Results 1171-1180 of 18718 for hepatitis

  1. An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD - Mayo Clinic

    Seropositive for human immunodeficiency virus, hepatitis B or antibodies to hepatitis B surface and core antigens, or hepatitis C; Has plasma cell leukemia ...

  2. Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer - Mayo Clinic

    ... hepatitis B (chronic or acute) or active hepatitis C infection. Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis ...

  3. Study of Pembrolizumab (MK-3475) in Combination With Dinaciclib (MK-7965) in Hematologic Malignancies (MK-3475-155) - Mayo Clinic

    Has a known history of or is positive for hepatitis B (hepatitis B surface antigen reactive) or hepatitis C (hepatitis C virus RNA [qualitative] is detected) ...

  4. Radiopharmaceutical therapy shows favorable results for people with tough-to-treat meningioma brain tumors, Mayo Clinic study finds

    No patients experienced life-threatening side effects, while 10 had severely low blood counts, one had grade 3 hepatitis and one had a grade 3 seizure possibly ...

  5. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

    ... hepatitis B surface antigen [antiHBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of hepatitis B virus (HBV) DNA levels.

  6. Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients with ALS - Mayo Clinic

    Positive test for Hepatitis B, Hepatitis C, HIV. Current use of immunosuppressant medication or use of such medication within 4 weeks of Screening visit ...

  7. A Study of the Safety and Effectiveness of Nivolumab for the Treatment of Advanced Non-Small Cell Lung Cancer - Mayo Clinic

    Active or chronic infection of hepatitis B virus or hepatitis C. Participating Mayo Clinic locations. Study statuses change often. Please contact the study ...

  8. Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma - Mayo Clinic

    ... hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or hepatitis C (anti ...

  9. Phase 1 Study of Oral TP-1454 - Clinical Trials

    Dose escalation in solid tumors with capsules only: Have known infection with hepatitis B, or hepatitis C. Patients with history of chronic hepatitis that is ...

  10. A Study of the Effectiveness and Safety of Vedolizumab Compared to Adalimumab for Participants with Ulcerative Colitis - Mayo Clinic

    Has chronic hepatitis B virus (HBV) infection* or chronic hepatitis C virus (HCV) infection (* HBV immune participants, ie, being hepatitis B surface ...